GlyTherix Ltd (GlyTherix), is a targeted radiotherapy company with a clinical stage product showing an excellent safety profile in high unmet need cancers. Our antibody, Miltuximab® specifically targets GPC-1, a protein found on solid tumours such as prostate, bladder, pancreatic, glioblastoma, oesophageal and ovarian cancers, and is not present in healthy tissue.
There is a large addressable market in the USA and Europe of US$21.7 billion per annum.
The company has a strong proprietary and intellectual property position covering the Miltuximab® antibody, epitope and the antigen. This provides robust and long-term protection for the commercialization of important new treatments to people with little hope.
GlyTherix has a strong management and research team and a highly experienced clinical advisory panel who have been intimately involved in commercialisation of targeted radiotherapies.
The Series B round of investment is now open with intention to close within 2 months.